Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol

Fig. 2

Diagram of the MET-FINGER trial. The main trial comparison is between the FINGER 2.0 Multimodal (combining a Structured Multimodal Lifestyle Intervention (SMLI) and metformin, where appropriate) vs the Self-Guided Multimodal intervention (SGMI). Metformin treatment is included in the FINGER 2.0 Multimodal Intervention through a trial-within-trial where participants who are eligible for metformin treatment will be randomly allocated to one of the three metformin/placebo treatments in addition to the SMLI. Ineligible participants for the metformin treatment will continue participation receiving the SMLI alone. The study, therefore, includes two screening and randomisation steps. The first screening step will assess eligibility for full study participation and eligible participants will be equally randomised to either the FINGER 2.0 or the SGMI. The second screening step will determine specific eligibility to the metformin treatment and eligible participants will be randomised as described above

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193